Rb S249 as an Emerging Biomarker in the Prognosis of Prostate Cancer

Biomarkers have become a potential tool in the diagnosis of cancer patients, allowing a more accurate diagnosis and treatment. Prostate cancer is the second most common type of cancer in men worldwide. In prostate cancer, it is important to identify which patients would benefit from early treatment. Here we report the combination of phosphorylation of the retinoblastoma protein (Rb) on serine 249 (Rb S249) wit with p39 expression as biomarkers for predicting prostate cancer. We performed an immunohistochemical analysis of Rb S249 and p39 expression. Our results indicate that there is an inverse relationship between Rb S249 and prostate adenocarcinoma. Hence, Rb S249 could help in determining a more accurate prognosis for prostate cancer patients. Support or Funding Information Funded by NIH-NIGMS #2R25GM096955 This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.